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http:WHAT THIS PAPER ADDS
This is the only prospective randomised trial on acute type B dissection. The deﬁnition of the acute dissection is
clearly deﬁned as is the outcome. In the highly specialised centres participating, the outcome was good and the
rate of thrombosis of the false channel can be estimated and be used as reference. Stent grafts induced
thrombosis of the false channel and were safe to implant.Objectives: Uncomplicated acute type B aortic dissection (AD) treated conservatively has a 10% 30-day mortality
and up to 25% need intervention within 4 years. In complicated AD, stent grafts have been encouraging. The aim
of the present prospective randomised trial was to compare best medical treatment (BMT) with BMT and Gore
TAG stent graft in patients with uncomplicated AD. The primary endpoint was a combination of incomplete/no
false lumen thrombosis, aortic dilatation, or aortic rupture at 1 year.
Methods: The AD history had to be less than 14 days, and exclusion criteria were rupture, impending rupture,
malperfusion. Of the 61 patients randomised, 80% were DeBakey type IIIB.
Results: Thirty-one patients were randomised to the BMT group and 30 to the BMTþTAG group. Mean age was
63 years for both groups. The left subclavian artery was completely covered in 47% and in part in 17% of the
cases. During the ﬁrst 30 days, no deaths occurred in either group, but there were three crossovers from the BMT
to the BMTþTAG group, all due to progression of disease within 1 week. There were two withdrawals from the
BMTþTAG group. At the 1-year follow up there had been another two failures in the BMT group: one
malperfusion and one aneurysm formation (p ¼ .056 for all). One death occurred in the BMTþTAG group. For
the overall endpoint BMTþTAG was signiﬁcantly different from BMT only (p < .001). Incomplete false lumen
thrombosis, was found in 13 (43%) of the TAGþBMT group and 30 (97%) of the BMT group (p < .001). The false
lumen reduced in size in the BMTþTAG group (p < .001) whereas in the BMT group it increased. The true lumen
increased in the BMTþTAG (p < .001) whereas in the BMT group it remained unchanged. The overall transverse
diameter was the same at the beginning and after 1 year in the BMT group (42.1 mm), but in the BMTþTAG it
decreased (38.8 mm; p ¼ .062).
Conclusions: Uncomplicated AD can be safely treated with the Gore TAG device. Remodelling with thrombosis of
the false lumen and reduction of its diameter is induced by the stent graft, but long term results are needed.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Article history: Received 13 August 2013, Accepted 12 May 2014, Available online 22 June 2014
Keywords: Acute type B dissection, Uncomplicated, Stent graft, Thrombosis, Remodellinglric and L. Canaud, CHU Arnaud de Villeneuve, Montpeiller; M. Janotta, Section of Vascular Surgery, Department of Surgery, University of Regensburg;
hel, Klinikum Nuernberg; M. Malina and Ti. Resch, Dept. Vascular Diseases, University Hospital, Malmö; H.-H. Eckstein and S. Ockert, Dept. Vascular
TUM Munich; T. Larzon, Section of Vascular Surgery; F. Carlsson, Department of Cardiology, Örebro University Hospital, Örebro; H. Schumacher, S.
, and P. Schaub Dept. Vascular Surgery, Hanau; J. Lammer, Dept. Radiology, General Hospital, Vienna; L. Lönn, Dept. Vascular Surgery and Radiology,
spitalet, Copenhagen; Rachel E. Clough, Dept.Vascular Surgery, St Guys Hospital, London; V. Rampoldi and S. Trimarchi, Policlinico San Donato, Milan; J.-
ani, APHP Hopital Europeen Georges Pompidou, Paris; D. Böckler and D. Kotelis, Dept. Vascular Surgery, University Clinics, Heidelberg; H. von Tenng-
, Dept. Radiology, University Clinics, Heidelberg; N. Mangialardi and S. Ronchey, Azienda Ospedaliera S. Filippo Neri, Rome; G. Dialetto, V. Monaldi
l, Naples; V. Matoussevitch, Department of Vascular and Endovascular Surgery, University Clinics, University of Cologne. ClinicalTrial.gov identiﬁer:
42274.
rresponding author. J. Brunkwall, Department of Vascular and Endovascular Surgery, University Clinics, University of Cologne, Kerpener Strasse 62,
Cologne, Germany.
il address: jan.brunkwall@uk-koeln.de (J. Brunkwall).
-5884/$ e see front matter  2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
//dx.doi.org/10.1016/j.ejvs.2014.05.012
286 J. Brunkwall et al.INTRODUCTION
Acute type B aortic dissection (AD) involving the descending
thoracic aorta has an approximately 10% 30-day mortality.1
The mortality of open surgery for complicated acute type B
dissection is up to 30%, and in malperfusion it reaches
50%.2,3 Alternative endovascular techniques such as aortic
membrane fenestration and stenting of side branches have
good patency rates but still result in high mortality.4e7
Placing a stent graft to cover the primary entry tear
shows good results in complicated acute type B dissection,
with a lower mortality.8e11
Systolic blood pressure around 100e120 mmHg after
treatment of acute uncomplicated type B AD results in a 30-
day mortality of 6e10%.1,12 Dilation of the false lumen af-
fects up to 50% of patients over 5 years, and survival ranges
from 50% to 82%.12,13 Complete thrombosis of the false
lumen is associated with better survival than a fully patent
false lumen in non-stent-grafted patients, but partial
thrombosis has the worst outcome.14 Another study,
though, shows that thrombosis of the false lumen was not
an independent factor for intervention.15 Involvement of
the abdominal aorta by dissection (DeBakey IIIb) also carries
a worse outcome than those affecting only the thoracic
aorta (DeBakeyIIIa).16
There are only two prospective randomised trials on un-
complicated dissection, the present ADSORB (Acute Dissec-
tion Stentgraft OR Best Medical Treatment) trial for acute
dissections and the INSTEAD trial (Investigation of STEnt
grafts in Acute Dissection) for dissections between 14 days
and 1 year (chronic). A newly published article revealed
different outcomes in those patients receiving TEVARFigure 1. Measurement sites performed by the Corelab.
C1 ¼ maximum diameter of true lumen, C2 ¼ minimum diameter
of true lumen, E1 ¼ maximum diameter of false lumen,
E2 ¼ overall transverse aortic diameter.between 2 weeks and 3 months,17 indicating that this time
period could be deﬁned as subacute instead of chronic.
The INSTEAD trial, including 136 patients with chronic
dissection showed that stent graft repair was associated
with expansion of the true lumen compared with those
treated medically and a lower all-cause and aortic-related
mortality than medical treatment alone at 5 years.18e20
The ADSORB trial is the only prospective randomised trial
for acute uncomplicated type B dissection.
The aim of the present prospective multicentre rando-
mised European study in uncomplicated type B dissection
(DeBakey III) is to compare the primary endpoint with
freedom from all of the following events at 1 year:
1. Incomplete or no false lumen thrombosis in any portion
of the false lumen parallel to the stent graft, excluding
the distal 2 cm, and in the BMT group at any point in the
descending thoracic aorta.
2. Aortic dilatation of 5 mm or the maximum diameter of
the descending thoracic aorta 55 mm.
3. Aortic rupture (descending thoracic or abdominal aorta)
with fresh blood outside the adventitia observed on
computed tomography (CT).
Ethical approval was given by the corresponding ethics
committee at each site.
MATERIALS AND METHODS
The protocol for the ADSORB trial has already been pub-
lished and will only be brieﬂy summarised here.21 Between
December 2008 and December 2010, patients presenting
with an acute uncomplicated type B dissection and without
any evidence of connective tissue disease were randomised
within 14 days of onset of symptoms. All patients were
immediately treated with blood pressure control and were
randomised to best medical treatment (BMT) alone or BMT
with endoluminal repair using a Gore TAG device
(TAGþBMT). The TAG treatment had to be done within 48
hours of randomisation. The analysis of the primary end-
points was based upon the intention-to-treat principle and
when separately noted, per protocol.
Patients with a double lumen dissection were included,
but not other variants of acute aortic syndrome. The pro-
portion of type IIIB dissections using DeBakey’s classiﬁcation
criteria was determined if the dissection involved the su-
perior mesenteric artery (SMA), inferior mesenteric artery
(IMA), any renal artery or the abdominal aorta. Otherwise it
was a type IIIA dissection. The proximal landing zone had
to be 2 cm in length and the device at least 15 cm long.
The oversizing should not be more than 10%, but the total
length of the device was left up to the treating team to
decide. Coverage of the left subclavian artery was allowed
in order to achieve an adequate proximal sealing zone, and
the local team decided upon the need for revascularisation
of the left subclavian artery. Coverage of the left common
carotid artery was not allowed. Blood pressure control
aimed to regulate the blood pressure to 120/80; blood
pressure was monitored during follow-up.
Table 1. Baseline patient demographics.
TAGþBMT BMT
Subjects randomized 30 31
Gender
Male 21 (70%) 27 (87%)
Female 9 (30%) 4 (13%)
Age (yrs)
N 30 31
Median 63.6 63.3
Range (41.8e75.6) (20.6e78.2)
Table 2. Number and class of drugs prescribed in order to control
blood pressure.
TAGþBMT
N ¼ 30
BMT only
N ¼ 31
Number of drugs prescribed
0 2 (7%) 2 (6%)
1 1 (3%) 0 (0.0%)
2 4 (13%) 3 (10%)
3 3 (10%) 6 (19%)
4 7 (23%) 3 (10%)
5 4 (13%) 6 (19%)
6 3 (10%) 2 (6%)
More than 6 6 (20%) 9 (29%)
Drug class
ACE inhibitor 18 (60%) 19 (61%)
Alpha-blocker 14 (47%) 15 (48%)
Beta-blocker 24 (80%) 26 (84%)
Calcium channel blocker 26 (87%) 23 (74%)
Diuretic 18 (60%) 20 (64%)
Vasodilator 7 (23%) 9 (29%)
Other hypertensive 9 (30%) 13 (42%)
Missing 4 (13%) 3 (10%)
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were analysed by an independent Corelab.
The Corelab examined study images for remodelling as
shown in Fig. 1 focusing on maximum diameter of the true
and false lumina, and the overall transverse aortic diameter.
Dissection-related mortality was deﬁned as death (a) within
30 days of initial treatment, (b) before hospital discharge,
(c) within 30 days of a secondary endoluminal or surgical
intervention, or (d) directly caused by the aortic dissection.
Statistics
Sample size calculation was based on the assumption of a
total sample size of 60 patients (30 per group) and 55% of
the control (BMTonly) group meeting the primary endpoint,
resulting in 80% power to detect a difference of at least
34% in the test (TAGþBMT) group under the intention to
treat analysis using a two-sided chi-square test. Data are
shown as median and range for continuous variables and as
counts with percentages for categorical variables. For
comparison by treatment group, ManneWhitney U tests
were used for continuous variables, and chi-square or
Fisher’s exact tests were used for categorical variables. A p
value <.05 was considered signiﬁcant.
RESULTS
Patient data
Sixty-one patients were randomised in 17 European centres
from December 2008 to December 2010, with one to 10
patients per centre. No log book was consequently ﬁlled
out, so that we cannot give any exact number of potential
candidates for randomisation. More than half of the pa-
tients logged were not included for various, mainly
anatomical, limitations. The top ﬁve enrolling included over
50% of the patients. Treatment cross-overs occurred in
three patients within 5 days of randomisation from the BMT
to TAGþBMT group and two patients were randomised to
TAGþBMT, but one withdrew consent and the other was
deemed ineligible due to too short a proximal landing zone
after secondary imaging studies were completed. Thus there
were 29 patients in the BMTþTAG group and 30 in the BMT
group.
Table 1 shows patient demographics. Twenty-seven men
and four women with a median age of 63.3 (range 21e78)
years were allocated to BMT and 21 men and 9 women,
median age 63.6 (range 42e76) years to TAGþBMT. The
body mass index (BMI) was 27.3 for the BMT and 27.2 forthe TAGþBMT groups respectively. There were no statisti-
cally signiﬁcant differences between the two groups for the
baseline demographics shown in Table 1.
The hypertensive medications were fairly similar in the
two groups the majority needing four or more medications
(Table 2).
In the TAGþBMT group 77% were type IIIB (n.s.) and in
the BMT group 84%.
The median time from onset of symptoms to random-
isation was 4.8 (range 0.3e14.3) days for the BMT group
and 4.6 (range 0.3e13.3) days for the TAGþBMT group. The
placement of the TAG device was a median 5.5 (range 1e
14) days after onset of symptoms (0.9 days after random-
isation). All patients were therefore treated within 14 days
of the onset of symptoms. In 60% of the cases there was a
complete or partial coverage of the left subclavian artery.
The BMT including several drugs for blood pressure
control was equally effective in both groups with half of the
patients having blood pressure less than 125/80 mmHg
according to their blood pressure log book.Primary efﬁcacy endpoint
Fourteen subjects failed due to inadequate/no imaging. All
subjects with inadequate imaging were counted in the 1-
year efﬁcacy endpoint calculation as failures; therefore,
only 31 BMT and 30 TAGþBMT were accounted for in the 1-
year efﬁcacy endpoint.
At 1 year, 15 (50.0%) of the 30 TAGþBMT patients had at
least one endpoint event and all 31 BMT patients did
(p < .001) (Tables 3 and 4).
Incomplete false lumen thrombosis was found in 13
(43%) of the TAGþBMT group and 30 (97%) of the BMT
group (p < .001). Aortic dilatation was found in 11 (37%) of
the TAGþBMT patients and 14 (45%) of the BMT patients.
Table 3. Per cent of false lumen thrombosis by treatment group
and on intention to treat basis.
TAGþBMT BMT p
Composite endpoint 15/30(50.0%) 31/31(100.0%) <.001
No false lumen thrombosis 13/30(43%) 30/31(97%) <.001
Aortic dilatation 11/30(37%) 14/31(45%) .500
Aortic rupture 0/30(0%) 0/31(0%) e
All p-values derived from two-sample chi-square test.
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domisation in either treatment group.Figure 2. Maximum true lumen by treatment group during follow
up. At 1 year, the true lumen expanded in the TAGþBMT group,
but did not so in the BMT group (p < .001).Per protocol analysis
Four of 23 TAG patients had no thrombosis. Among the
remainder, eight TAG patients Corelab analyses did not
report false lumen thrombosis or did not have 1-year
imaging.
Twenty-one of 23 BMT patients had no thrombosis, and
eight did not have 1-year imaging sent to the Core Lab.Remodelling
There was no baseline difference in average maximum false
lumen diameter (Fig. 2) (TAGþBMT 23.9 vs. BMT 22.1 mm,
p ¼ .791) or in maximum true lumen diameter (Fig. 3)
(TAGþBMT 22.5 vs. BMT 23.6 mm, p ¼ .83) between the
two groups. However, at the 1-year follow-up, the average
maximum false lumen diameter was 18.5 mm for
TAGþBMT versus 25.1 mm for BMT, p < .001; the
maximum true lumen diameter was 32.2 mm for TAGþBMT
versus 25.5 mm for BMT, p < .001.
The maximum false lumen diameter decreased in the
BMTþTAG group by 7.0 mm compared to an increase of
4.3 mm in the BMT group (p < .001). The maximum true
lumen diameter increased in the BMTþTAG group by
8.4 mm compared to 1.9 mm for BMT (p ¼ .022).
The overall transverse diameter was the same at the
beginning, but after 1 year the BMT group remained same
but the BMTþTAG group decreased in size (Fig. 4;
TAGþBMT 38.8 mm vs. BMT 42.1 mm, p ¼ .062). An
example of the positive effect of TAG in acute uncompli-
cated dissection is seen in Fig. 5.Table 4. Per protocol analysis at 1 year. Only patients eligible for
evaluation are reported.
TAGþBMT BMT p
16/31 30/30 <.001
Due to event 5 22
Incomplete 11 8
No false lumen thrombosis 14/31 29/30 <.001
Due to event 4 21
Incomplete 7 8
Aortic dilatation 11/31 14/30 .1
Due to event 2 7
Incomplete 8 5
p-Values calculated by two-sample chi-square test.Dissection-related mortality
There were no deaths within 30 days. There was one death
in the TAGþBMT group during follow-up caused by cardiac
arrest which was not reported as dissection related; how-
ever, no autopsy was performed.DISCUSSION
ADSORB is the ﬁrst and only prospective randomised clinical
trial of acute uncomplicated type B dissection. The primary
endpoints were false lumen thrombosis, aortic dilatation,
and aortic rupture. The composite endpoint analysis
revealed that TAGþBMT group results were signiﬁcantly
more effective than the BMT-only group results, even
though many failures in the stent graft group were due to
missing data. Further, there was signiﬁcantly more remod-
elling in the ﬁrst year among the patients in the TAGþBMTFigure 3. Evolution of the false lumen by treatment group during the
one year follow up. At 1 year, the false lumen decreased in size in the
TAGþBMT group but did not so in the BMT group (p < .001).
Figure 4. Aortic diameter was similar at baseline and the difference
at 1 year did not reach statistical signiﬁcance (p < .062).
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dissection-related mortality in either group. There was only
one death within the ﬁrst year, which was reported as a
myocardial infarction; however, a post mortem was not
performed so that there can be no certainty about the
cause of death.Figure 5. (A) An acute dissection of the thoracic aorta (DeBakeyIII). (B) T
seen.Best medical treatment
The accepted medical treatment for uncomplicated acute
type B dissection has a reported mortality of approximately
10% at 30 days, 20e40% at 5 years, and up to 60% at 10
years.22e24 BMT was given to both arms of this study and
the mortality at 30 days was zero, indicating the efﬁcacy of
modern antihypertensive drugs. We had not powered for
mortality so this rate is to be regarded with caution (only 1
death would mean 3%). The majority of patients required at
least three different types of antihypertensive drugs. Blood
pressure monitors were given to all patients so that they
could record their own blood pressures at home during
different times of the day. This resulted in 50% having
desired blood pressure control. There are no other reported
series on the measured effectiveness of blood pressure
medication in dissection so this cannot be compared with
other series.
Comparison to other dissection treatment trials
The TAG device has also been studied in acute complicated
dissections.25 The results from that study were similar to
the ADSORB results with a signiﬁcant decrease in maximum
aortic diameter, true lumen increase, and false lumen
diameter decrease. Owing to different analyses, there
cannot be a direct comparison. The ADSORB trial had nohe same patient 2 years after stent graft. No signs of a dissection is
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reported two ruptures (6%) at 1 year follow-up.
The INSTEAD trial was a randomised controlled trial for
treatment with the Talent Device versus BMT in chronic
uncomplicated type B dissections. The 1-year results of the
INSTEAD trial revealed no difference in the maximum aortic
diameter between the two groups. The true lumen diam-
eter was signiﬁcantly greater and the false lumen diameter
was signiﬁcantly less for those treated with an endoluminal
device compared with BMT alone. Complete false lumen
thrombosis was more frequent in the Talent group but the
number with incomplete false lumen thrombosis was the
same.19
Current risk stratiﬁcation of uncomplicated type B patients
The survival of patients treated medically can be as low as
50% at 5 years, and therefore attempts have been made to
risk stratify uncomplicated patients.22,23,26 Factors of
importance for poor outcome include partial thrombosis of
the false lumen, aortic diameter greater than 4 cm, false
lumen diameter of more than 22 mm, large proximal entry
tears, and entry tears on the concave inner curvature of the
distal arch as opposed to the convex outer curvature.13,27e
32 A recent International Registry of Acute Aortic Dissection
analysis showed that aortic expansion occurred in the ma-
jority of patients with acute type B dissection. In a multi-
variate analysis, white race and an initial aortic diameter
less than 4.0 cm were associated with increased aortic
expansion. Female gender, intramural haematoma, and use
of calcium channel blockers were associated with decreased
aortic expansion.33
Problems using thrombosis of the false lumen as an end
point
The diagnosis of false lumen thrombus is deﬁned as the
absence of contrast media in the false lumen on a CT scan,
which is inaccurate compared to magnetic resonance im-
aging with a blood pool agent.34 The acquisition of images
on a CT scan is usually triggered by the arrival of intrave-
nously injected contrast media in the ascending aorta. No
previous study or trial has published a protocol for the
acquisition of CT data. The volume of thrombus measured
by magnetic resonance imaging using a blood pool agent is
ﬁve to six times smaller than techniques using ﬁrst-pass
imaging.34 Thus, protocols for clinical trials using false
lumen thrombosis as an endpoint should include magnetic
resonance imaging with a blood pool agent. Secondly one
might discuss the meaning of measuring the thrombosis
rate just outside the stent graft. Previous reports indicate
that almost no thrombosis will occur distal to the visceral
arteries in patients with a type IIIB dissection. Thus, one
cannot expect thrombosis distal to the stent graft. Secondly,
the length of stent graft required for treating acute
dissection is unclear. A 15-cm stent graft was considered
safe, but it is not known how much the paraplegia rate
would increase if the whole descending thoracic aorta was
covered.The question remains as to whether endovascular treat-
ment with a stent graft in the acute phase of acute type B
aortic dissection is associated with improved survival
compared with medical treatment alone, and can only be
demonstrated with a larger randomised controlled trial and
longer follow-up.
Study limitations
All centres taking part in the ADSORB trial were experienced
in both medical treatment and endovascular repair of pa-
tients with dissection. Most of the recruiting centres were
tertiary referral hospitals, so there may be a bias in the
selection of patients with type B aortic dissection included
in the trial. The good results achieved from endovascular
repair may not be replicated by less experienced centres.
There were challenges in obtaining quality follow-up imag-
ing resulting in 14 failures due to imaging issues/dropouts.
Additionally, the ADSORB trial was not powered for
mortality.
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